Ajanta Pharma Ltd (Ajanta Pharma) focuses on the development and commercialization of novel generic products. The company offers medicines in therapeutic areas including cardiology, ophthalmology, dermatology, antimalarial, gastroenterology, antihistamine, respiratory, and pain management. It offers anti-diabetics, anti-malarial, and antibiotics, besides drugs for cardiac, orthopedic, pediatric, gynecological, nephrology and respiratory conditions, and general health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ajanta Pharma has pursued multiple research and development (R&D) programs, including novel nanotechnology-based micro-emulsion formulations for ophthalmic dosage forms, preservative-free ophthalmic products in innovative bottles, and non-comedogenic dermatological formulations. The company is applying advanced tangential drug layering technology for new product development and is developing oral solid dosage forms by combining two processing steps to enhance quality and shorten processing time. Ajanta Pharma is also prioritizing conversion of tablet coatings from non-aqueous to aqueous systems, developing complex generic products for ANDA filings in the US market, and designing robust, cost-effective formulations across diverse therapeutic categories. The company is further engaged in developing and launching products for neuropathic pain management and conducting in-house synthesis of process impurities and analytical methodologies. Ajanta Pharma’s R&D unit, located in Mumbai, develops differentiated generic products. The unit supports formulation development, process chemistry, and analytical development, emphasizing first-to-market products that provide convenience and improved patient compliance. In FY2026, the company spent INR 2,603.7 million on its R&D activities, which, as a percentage of revenue, stood at 4.7% and grew 12.3% YoY. The company had 49 active ANDAs, including six approvals in FY2025; 47 products on shelf, including three launched in FY20256; 19 pending approvals; and five ANDAs filed in FY2026 for the US Generics.